Filing Flows › Enovis (ENOV) › Q2 2026 › vs Q1 2026
Enovis (ENOV) Q2 2026 vs Q1 2026 (quarter over quarter)
Enovis's revenue fell $6.4M (-1%) from $589M in Q1 2026 to $583M in Q2 2026. The biggest changes: Reconstructive −$22.6M (-7%); Prevention & Recovery +$16.2M (+6%).
Enovis, Q2 2026: revenue $583M (+3% year over year), operating margin 3.0%, net loss $1.0M, operating cash flow $75.0M. The chart draws each line against Q1 2026, the increases inside each band.
Margins
| Q2 2026 | Q1 2026 | Change | |
|---|---|---|---|
| Free cash flow margin | 5.3% | -4.9% | +10.2 pts |
Every line
| Line | Q2 2026 | Q1 2026 | Change | % |
|---|---|---|---|---|
| Reconstructive | $295M | $317M | −$22.6M | -7% |
| Prevention & Recovery | $288M | $272M | $16.2M | +6% |
| Revenue | $583M | $589M | −$6.4M | -1% |
| Net loss | $1.0M | $8.4M | −$7.4M | -88% |
| Costs & expenses | $584M | $598M | −$13.8M | -2% |
| Operating costs | $565M | $583M | −$17.3M | -3% |
| Interest & other, net | $9.9M | $5.9M | $4.0M | +68% |
| Income tax | $8.5M | $9.0M | −$544K | -6% |
| Cost of revenue | $224M | $224M | −$133K | -0.1% |
| Research & development | $31.7M | $31.5M | $153K | +0.5% |
| SG&A | $264M | $283M | −$19.1M | -7% |
| Other operating costs | $46.4M | $44.6M | $1.8M | +4% |
| Operating cash sources | $80.0M | $82.1M | −$2.1M | -3% |
| Depreciation & amortization | $71.0M | $73.4M | −$2.3M | -3% |
| Share-based compensation | $9.0M | $8.8M | $218K | +2% |
| Net loss absorbed | $1.0M | $8.4M | −$7.4M | -88% |
| Working capital & other | $3.9M | $49.7M | −$45.8M | -92% |
| Operating cash flow | $75.0M | $24.0M | $51.1M | +213% |
| Free cash flow (OCF − capex) | $31.1M | −$28.9M | $60.0M | — |
| Capital expenditures | $43.9M | $52.8M | −$8.9M | -17% |
Questions
How much did Enovis's revenue grow quarter over quarter in Q2 2026?
Enovis's revenue fell $6.4M (-1%) from $589M in Q1 2026 to $583M in Q2 2026.
What drove Enovis's revenue change in Q2 2026?
Reconstructive −$22.6M (-7%); Prevention & Recovery +$16.2M (+6%).